Please sign in to follow a disease.
SIGA Technologies
Clinical trials sponsored by SIGA Technologies, explained in plain language.
Develops pharmaceuticals for viral infections, including smallpox treatment TPOXX.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Does a smallpox drug weaken the vaccine? new study aims to find out. Results expected Jan 2027 (estimated)
-
Can common kidney drugs weaken the smallpox antiviral TPOXX?
Disease control CompletedResearchers are testing whether four common phosphate binders change how the body processes the smallpox antiviral TPOXX. The study enrolls 44 healthy adults aged 18 to 50 with normal phosphorus levels. Each participant receives TPOXX alone and with each binder in a five-period c…
Phase 4 • Sponsor: SIGA Technologies • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Smallpox drug put to the test in heavier adults
Disease control CompletedResearchers are studying the smallpox antiviral TPOXX in adults who weigh more than 120 kg. The trial measures how the drug moves through the body and checks for side effects over a week of dosing. The goal is to see whether this group processes the drug differently, which could …
Phase 4 • Sponsor: SIGA Technologies • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Smallpox drug put to the test in healthy volunteers
Prevention CompletedResearchers are testing an antiviral drug called tecovirimat to see if it is safe and well tolerated when taken by mouth for 14 days. The trial enrolls healthy adults aged 18 to 80 and compares tecovirimat with a placebo. The goal is to gather safety information that could suppor…
Phase 3 • Sponsor: SIGA Technologies • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Smallpox drug put to the test: can TPOXX be taken safely for a month?
Prevention CompletedResearchers are studying whether an antiviral drug called tecovirimat (TPOXX) is safe and well tolerated when taken by mouth twice daily for 28 days. The trial enrolls healthy adults aged 18 to 80 and compares TPOXX with a placebo. The main goal is to measure drug levels in the b…
Phase 3 • Sponsor: SIGA Technologies • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Antiviral tecovirimat put to the test for smallpox threat
Prevention CompletedResearchers tested two doses of tecovirimat, an antiviral drug, in healthy volunteers to see how safe and well-tolerated it is. Participants took a daily oral dose for 14 days, and researchers monitored side effects and measured drug levels in the blood. The goal was to find the …
Phase 2 • Sponsor: SIGA Technologies • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC